InflaRx (IFRX) Short-term Investments (2016 - 2026)
InflaRx (IFRX) posted Short-term Investments of $29.0 million for Q1 2026, down 18.02% sequentially from $35.4 million in Q4 2025, and up 11514.96% YoY from N/an in Q1 2025.
InflaRx (IFRX) Short-term Investments (2016 - 2026) Analysis & Trends
InflaRx has reported Short-term Investments for 11 years, with the latest figure at $29.0 million in Q1 2026.
- Quarterly Short-term Investments rose 11514.96% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.0 million (up 11514.96% YoY) and the FY2025 annual result came in at $34.4 million, down 7.81% from the prior year.
- Short-term Investments declined to $29.0 million in Q1 2026 per IFRX's latest filing, from $35.4 million in the prior quarter.
- Over five years, Short-term Investments peaked at $56.0 million in Q1 2022 and troughed at $239668.8 in Q3 2022.
- A 5-year average of $19.0 million and a median of $9.7 million in 2023 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2022 and 2025: Short-term Investments sank 99.62% in 2022, then surged 15370.9% in 2025.
- Over 5 years, Short-term Investments stood at $3.0 million in 2022, then jumped by 229.1% to $9.7 million in 2023, then surged by 278.09% to $36.8 million in 2024, then slipped by 3.8% to $35.4 million in 2025, then retreated by 18.02% to $29.0 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $29.0 million, $35.4 million, and $44.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.04 Mn |
| Dec 31, 2025 | 35.43 Mn |
| Sep 30, 2025 | 44.65 Mn |
| Jun 30, 2025 | 39.61 Mn |
| Mar 31, 2025 | 250,044.50 |
| Dec 31, 2024 | 36.83 Mn |
| Sep 30, 2024 | 34.80 Mn |
| Jun 30, 2024 | 256,035.41 |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 9.74 Mn |
| Sep 30, 2023 | 258,609.91 |
| Jun 30, 2023 | 20.64 Mn |
| Mar 31, 2023 | 8.55 Mn |
| Dec 31, 2022 | 2.96 Mn |
| Sep 30, 2022 | 239,668.82 |
| Jun 30, 2022 | 253,332.06 |
| Mar 31, 2022 | 56.03 Mn |
| Dec 31, 2021 | 31.12 Mn |
| Sep 30, 2021 | -47.78 Mn |
| Jun 30, 2021 | 66.04 Mn |